Compare FTAI Aviation Ltd (FTAI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Novavax Inc — how do they compare? FTAI Aviation Ltd trades at $169.97 (market cap $17.57B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: FTAI Aviation Ltd is far larger — about 9.7× Novavax Inc's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Novavax Inc for 59 Days on average.
| FTAI | NVAX | |
|---|---|---|
Market Cap | $17.57B | $1.82B |
Volume | 1,905,014 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $310.04 | $12.75 |
52-Week Low | $152.80 | $6.22 |
Typical Hold Time | 23 Days | 59 Days |
Enterprise Value | $20.69B | $1.39B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $171.06, down 2.16% amid a bearish technical signal, with support at $169 and resistance at $173. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS estimates. Recent developments include a $500M share buyback program and a 5-year Asia-Pacific maintenance deal with GMF, signaling strategic growth initiatives.
The outlook is mixed: robust analyst consensus (100% buy ratings, $321.25 price target) and shareholder-friendly actions support upside, but consecutive earnings misses, negative operating cash flow, and high valuation ratios (P/E 37.35) pose risks. Investors should weigh growth in aerospace segments against execution challenges and macroeconomic headwinds.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
